Relmada Therapeutics IncNASDAQ:RLMD
- LAST PRICE3.0200
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots1.2100/ 2
- Ask / Lots4.8300/ 2
- Open / Previous Close--- / 3.0200
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | RLMD |
|---|---|---|
| 09:32 ET | 804 | 3.02 |
| 09:33 ET | 500 | 2.9761 |
| 09:35 ET | 1061 | 3.04 |
| 09:37 ET | 2049 | 3.13 |
| 09:42 ET | 400 | 3.11 |
| 09:44 ET | 100 | 3.035 |
| 09:48 ET | 6351 | 3.06 |
| 09:50 ET | 1186 | 3.13 |
| 09:51 ET | 3073 | 3.2 |
| 09:53 ET | 100 | 3.185 |
| 09:55 ET | 200 | 3.18 |
| 09:57 ET | 2006 | 3.14 |
| 10:00 ET | 1000 | 3.165 |
| 10:02 ET | 100 | 3.17 |
| 10:04 ET | 515 | 3.14 |
| 10:08 ET | 1713 | 3.16 |
| 10:13 ET | 200 | 3.14 |
| 10:15 ET | 1130 | 3.145 |
| 10:18 ET | 3709 | 3.115 |
| 10:20 ET | 980 | 3.13 |
| 10:22 ET | 660 | 3.08 |
| 10:24 ET | 100 | 3.135 |
| 10:27 ET | 100 | 3.11 |
| 10:36 ET | 500 | 3.1357 |
| 10:38 ET | 500 | 3.17 |
| 10:40 ET | 300 | 3.13 |
| 10:45 ET | 694 | 3.13 |
| 10:47 ET | 100 | 3.13 |
| 10:49 ET | 100 | 3.13 |
| 10:54 ET | 200 | 3.13 |
| 10:58 ET | 100 | 3.13 |
| 11:00 ET | 100 | 3.13 |
| 11:02 ET | 100 | 3.13 |
| 11:03 ET | 652 | 3.11 |
| 11:05 ET | 1800 | 3.2 |
| 11:07 ET | 2724 | 3.18 |
| 11:09 ET | 1013 | 3.18 |
| 11:12 ET | 758 | 3.205 |
| 11:14 ET | 100 | 3.18 |
| 11:18 ET | 1099 | 3.19 |
| 11:21 ET | 200 | 3.19 |
| 11:25 ET | 100 | 3.19 |
| 11:30 ET | 1006 | 3.205 |
| 11:32 ET | 100 | 3.21 |
| 11:38 ET | 100 | 3.21 |
| 11:41 ET | 100 | 3.21 |
| 11:45 ET | 200 | 3.21 |
| 11:50 ET | 400 | 3.205 |
| 11:57 ET | 734 | 3.185 |
| 12:01 ET | 985 | 3.175 |
| 12:14 ET | 300 | 3.17 |
| 12:26 ET | 100 | 3.11 |
| 12:28 ET | 126 | 3.13 |
| 12:30 ET | 100 | 3.11 |
| 12:33 ET | 100 | 3.13 |
| 12:37 ET | 600 | 3.11 |
| 12:46 ET | 200 | 3.125 |
| 12:57 ET | 267 | 3.1 |
| 01:00 ET | 100 | 3.11 |
| 01:02 ET | 400 | 3.075 |
| 01:04 ET | 100 | 3.05 |
| 01:08 ET | 100 | 3.075 |
| 01:40 ET | 100 | 3 |
| 01:42 ET | 100 | 3.02 |
| 01:44 ET | 300 | 3 |
| 01:49 ET | 100 | 3.02 |
| 01:51 ET | 300 | 2.99 |
| 01:56 ET | 637 | 3 |
| 01:58 ET | 200 | 3 |
| 02:05 ET | 5714 | 3 |
| 02:12 ET | 2070 | 3 |
| 02:18 ET | 790 | 3 |
| 02:25 ET | 200 | 3 |
| 02:32 ET | 100 | 3 |
| 02:38 ET | 665 | 3.01 |
| 02:39 ET | 100 | 3 |
| 02:41 ET | 1758 | 3 |
| 02:43 ET | 1200 | 2.99 |
| 02:45 ET | 100 | 3 |
| 02:48 ET | 200 | 3 |
| 02:50 ET | 100 | 2.995 |
| 02:52 ET | 100 | 2.995 |
| 02:54 ET | 2446 | 3.04 |
| 02:56 ET | 100 | 3.04 |
| 03:14 ET | 900 | 3.04 |
| 03:15 ET | 300 | 3.05 |
| 03:17 ET | 4615 | 3.04 |
| 03:19 ET | 100 | 3.04 |
| 03:21 ET | 100 | 3.04 |
| 03:24 ET | 100 | 3.04 |
| 03:28 ET | 500 | 3.03 |
| 03:32 ET | 100 | 3.03 |
| 03:33 ET | 421 | 3.03 |
| 03:35 ET | 170 | 3.03 |
| 03:37 ET | 100 | 3.02 |
| 03:39 ET | 2628 | 3 |
| 03:42 ET | 700 | 3.02 |
| 03:44 ET | 2200 | 2.99 |
| 03:46 ET | 1001 | 2.99 |
| 03:48 ET | 1004 | 3.005 |
| 03:50 ET | 300 | 3.005 |
| 03:51 ET | 2191 | 3.03 |
| 03:53 ET | 100 | 3.025 |
| 03:57 ET | 500 | 3.01 |
| 04:00 ET | 13408 | 3.02 |
Nov 14, 2024
Relmada Therapeutics Initiates Phase 1 Dosing with REL-P11 for Metabolic Disease, from 7:30AM ET on Thursday Nov 14, 2024 by Dow Jones
7:30AM ET on Thursday Nov 14, 2024 by Dow Jones
Nov 7, 2024
Press Release: Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update, from 4:32PM ET on Thursday Nov 07, 2024 by Dow Jones
4:32PM ET on Thursday Nov 07, 2024 by Dow JonesRelmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update, from 4:10PM ET on Thursday Nov 07, 2024 by Dow Jones
4:10PM ET on Thursday Nov 07, 2024 by Dow JonesPress Release: Relmada Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update, from 4:10PM ET on Thursday Nov 07, 2024 by Dow Jones
4:10PM ET on Thursday Nov 07, 2024 by Dow Jones
Nov 4, 2024
Relmada Therapeutics to Report Third Quarter 2024 Financial Results on November 7, 2024, from 4:30PM ET on Monday Nov 04, 2024 by Dow Jones
4:30PM ET on Monday Nov 04, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Relmada Therapeutics Inc | 91.1M | -1.1x | --- |
Hillevax Inc | 91.1M | -0.6x | --- |
Genelux Corp | 90.8M | -2.8x | --- |
Regulus Therapeutics Inc | 93.0M | -1.3x | --- |
Invivyd Inc | 88.4M | -0.4x | --- |
Annovis Bio Inc | 94.1M | -1.8x | --- |
Company Information
Relmada Therapeutics, Inc. is a clinical-stage biotechnology company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). The Company is focused on the development of esmethadone (d-methadone, dextromethadone, REL-1017), an N-methyl-D-aspartate (NMDA) receptor antagonist. Esmethadone, an isomer of methadone, is a new chemical entity (NCE) that potentially addresses areas of high unmet medical need in the treatment of central nervous system (CNS) diseases and other disorders. The Company’s lead program, REL-1017, is a NCE and novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission. REL-1017 is in late-stage development as an adjunctive treatment for MDD in adults. Its esmethadone, is being developed as a rapidly acting, oral agent for the treatment of depression and other potential indications.
Contact Information
- Headquarters
- 2222 Ponce De Leon Blvd. 3Rd FloorCORAL GABLES, FL, United States 33134
- Phone
- 646-876-3459
- Fax
- ---
Executives
- Independent Chairman of the Board
- Charles Casamento
- Chief Executive Officer, Director
- Sergio Traversa
- Chief Financial Officer
- Maged Shenouda
- Chief Accounting, Compliance Officer
- Charles Ence
- Acting Chief Scientific Officer
- Paolo Manfredi
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $91.1M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 30.2M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.38 |
EPS | $-2.87 |
Book Value | $2.84 |
P/E Ratio | -1.1x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
